

## FUND DESCRIPTION

## "Where health care meets technology"

Companies within this fund are focused on, and are expected to benefit from, extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements, and advancements in genomics into their business.

## INVESTMENT OBJECTIVE

This actively managed fund seeks to achieve long-term growth of capital by investing primarily, under normal circumstances, in global equity securities of companies that are, or are expected to be, focused on extending and enhancing the quality of human and other life through technological and scientific developments, improvements, and advancements in genomics.

## WHY INVEST?

## 1. Exposure to innovation

Aims for thematic multi-cap exposure to innovative technologies, including: health care revolution, biotechnology, genomic advancements, and DNA sequencing.

## 2. Growth potential

Aims to capture long-term growth with a low correlation of relative returns to traditional growth strategies and negative correlation to value strategies.

## 3. Tool for diversification

Offers a tool for diversification due to little overlap with traditional indices. It can be a complement to traditional value/growth strategies.

## 4. Grounded in research

Combines top-down and bottom-up research in its portfolio management to identify innovative companies and convergence across markets.

FUND DETAILS  
AS AT 30.12.22

Series	A, F, O, D
Type	Equity Sector Weights
Currency	CAD/USD
Inception Date	04.10.2021 <sup>1</sup>
Management Fee (Series F & D)	0.8%
Management Fee (Series A)	1.8%
Management Fee (Series O)	Negotiable with Emerge Canada Inc.
Trailer Fees (Series A)	1.0% <sup>2</sup>
Sales Commissions (Series A)	Upto 5% of purchase amount <sup>3</sup>
Min. Investment (\$)	Based on fund series type <sup>4</sup>
Typical number of holdings	46
Portfolio Manager	Emerge Canada Inc.
Sub-advisors	ARK Investment Management LLC Emerge Capital Management Inc. <sup>5</sup>

TOP 10 HOLDINGS  
AS AT 30.12.22

Accolade, Inc.	11.3%
Adaptive Biotechnologies Corporation	5.3%
Arcturus Therapeutics Holdings Inc.	4.8%
ATAI Life Sciences NV	4.5%
Beam Therapeutics Inc.	4.0%
Butterfly Network, Inc.	4.0%
Berkeley Lights, Inc.	3.9%
CareDx, Inc.	3.8%
Codexis, Inc.	3.8%
Cerus Corporation	3.7%

SECTOR WEIGHTS  
AS AT 30.12.22

Healthcare	97.2%
Information Technology	2.8%

GEOGRAPHIC BREAK UP  
AS AT 30.12.22

Americas	88.8%
Europe	7.8%
UK	3.4%

## FUND CODES AND TICKER

	TICKER	CAD CODE	USD CODE
<b>SERIES A</b>	EAGBA	ECI200	ECI201
<b>SERIES F</b>	EAGBF	ECI210	ECI211
<b>SERIES O</b>	EAGBO	ECI220	ECI221
<b>SERIES D</b>	EAGBD	ECI230	ECI231



## PORTFOLIO MANAGER (SUB-ADVISOR)


**Catherine D. Wood**

Chief Investment Officer

ARK Investment Management LLC


Catherine registered ARK Investment Management LLC ("ARK") as an investment adviser with the U.S. Securities and Exchange Commission in January 2014. With over 40 years of experience identifying and investing in innovation, Catherine founded ARK to focus solely on disruptive innovation while adding new dimensions to research. Previously, she completed twelve years at AllianceBernstein as Chief Investment Officer of Global Thematic Strategies with over \$5 billion in assets under management. Before AllianceBernstein, she worked for eighteen years with Jennison Associates as Chief Economist, Equity Research Analyst, Portfolio Manager, and Director. Catherine started her career in Los Angeles at the Capital Group as an Assistant Economist.

**MARKET CAPITALIZATION AS AT 30.12.22**



**FUND DESCRIPTION**

Pharmaceutical Innovations  
Agricultural Biotechnology  
Genomic Sequencing  
Genomic analysis



**RISK RATING**

Emerge Canada Inc. has rated the volatility of this Fund as medium. This rating is based on how much the Fund's returns have changed from year to year. It doesn't tell you how volatile the Fund will be in the future. The rating can change over time. A fund with a low risk rating can still lose money.



**FOOTNOTES**

1. Mutual Fund Series of this existing ETF was officially launched on October 4th, 2021.
2. Trailing Fee – We pay a monthly or quarterly trailing commission of 1.0% to your Dealer on your Series A Units. The trailing commission is a percentage of the value of your Units.
3. Sales Commission - If you buy Series A Units, the commission you negotiate (up to 5.0% of your purchase amount) is deducted from your purchase amount and paid by you, through us, to your Dealer.
4. Series A: \$1000; Series F: \$1000 (waived off for self-directed investors); Series O: \$20 million
5. Emerge Canada Inc. has appointed Emerge Capital Management Inc. as sub-adviser, who has retained ARK investment Management LLC to provide investment advice to the Emerge ARK ETFs / Mutual Funds.

**For more information, contact Emerge Canada Inc. or your advisor for the fund's simplified prospectus and other disclosure documents.**

Commissions, management fees, brokerage fees and expenses may be associated with an investment in Mutual Funds. Before investing, you should carefully consider the Mutual Fund's investment objectives, strategies, risks, charges and expenses. This and other information are in the Emerge funds prospectus, which may be obtained by visiting [www.emergecm.ca](http://www.emergecm.ca) or [www.sedar.com](http://www.sedar.com). Please read the prospectus carefully before you invest. An investment in a Mutual Fund is subject to risks and you can lose money on your investment. Detailed information regarding the specific risks of the Mutual Funds can be found in the prospectus. There can be no assurance that the Mutual Fund will achieve its investment objective. The Mutual Fund's portfolio is more volatile than broad market averages. Units of the Mutual Fund are bought and sold at market price and there can be no guarantee that an active trading market for the Mutual Fund units will develop or be maintained, or that their listing will continue or remain unchanged. Mutual Funds are not guaranteed. Their values change frequently. Past performance may not be repeated. The statements contained in this document are based on information believed to be reliable and are provided for information purposes only. Where such information is based in whole or in part on information provided by third parties, we cannot guarantee that is accurate, complete or current at all times. This document does not provide investment, tax or legal advice, and is not an offer or solicitation to buy. Graphs and charts are used for illustrative purposes only and do not reflect future values or returns on investment. Particular investment strategies should be evaluated according to an investor's investment objectives and tolerance for risk. Emerge Canada Inc. and related entities are not liable for any error or omission in the information or for any loss or damage suffered. Certain statements in this marketing profile include forward-looking statements and those statement identified by the expressions "believe", "will" and similar expressions to the extent they relate to the Emerge Funds or Emerge. These forward-looking statements are subject to a number of risks and uncertainties and are based on several assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from current expectations. Forward-looking statements are not guarantees of future results. The top ten holdings, sector weights, geographic allocations and market capitalization are included to illustrate examples of the securities and sectors, geographics and market caps that the fund held as at a particular date and may not be representative of the fund's current or future investments and may change at any time.